J
Joan S. Brugge
Researcher at Harvard University
Publications - 302
Citations - 51153
Joan S. Brugge is an academic researcher from Harvard University. The author has contributed to research in topics: Proto-oncogene tyrosine-protein kinase Src & Phosphorylation. The author has an hindex of 115, co-authored 286 publications receiving 47965 citations. Previous affiliations of Joan S. Brugge include Howard Hughes Medical Institute & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Peptide analysis of the transformation-specific antigen from avian sarcoma virus-transformed cells.
TL;DR: Sera from rabbits bearing tumors induced by avian sarcoma virus were ussed to immunopecipitate virus-specific proteins from extracts of chicken, hamster, and field vole cells transformed by ASV, suggesting that the 60K protein is virus coded.
Journal ArticleDOI
Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2
Devin Worster,Tobias Schmelzle,Tobias Schmelzle,Nicole L. Solimini,Eric S. Lightcap,Bjorn Millard,Gordon B. Mills,Joan S. Brugge,John G. Albeck +8 more
TL;DR: In this paper, the abundance of cyclin-dependent kinase inhibitors p21Cip1 and p57Kip2 increased in response to IGF-1 or insulin, but decreased when compared to EGF.
Journal ArticleDOI
Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer.
Abigail E. Witt,Lisa M. Hines,Nicole L. Collins,Yanhui Hu,Ruwanthi N. Gunawardane,Donna Moreira,Jacob Raphael,Daniel Jepson,Malvika Koundinya,Andreas Rolfs,Barbara Taron,Steven J. Isakoff,Joan S. Brugge,Joshua LaBaer +13 more
TL;DR: The functional activity of a subset of the BC1000 collection was evaluated in cell-based assays that monitor changes in cell proliferation, migration, and morphogenesis in MCF-10A mammary epithelial cells expressing a variant of ErbB2 that can be inducibly activated through dimerization.
Journal ArticleDOI
PTK6 regulates IGF-1-induced anchorage-independent survival.
Hanna Y. Irie,Yashaswi Shrestha,Laura M. Selfors,Fabianne Frye,Naoko Iida,Wang Zhigang,Lihua Zou,Jun Yao,Yiling Lu,Charles B. Epstein,Sridaran Natesan,Andrea L. Richardson,Kornelia Polyak,Gordon B. Mills,William C. Hahn,William C. Hahn,Joan S. Brugge +16 more
TL;DR: The combined genomic and proteomic approaches in this report provide an effective strategy for identifying oncogenes and their mechanism of action and highlight PTK6 as a critical regulator of anchorage-independent survival of breast and ovarian tumor cells via modulation of IGF-1 receptor signaling.
Journal ArticleDOI
Thrombin receptor activation and integrin engagement stimulate tyrosine phosphorylation of the proto-oncogene product, p95vav, in platelets.
TL;DR: Results show that Vav phosphorylation by tyrosine kinases occurs during platelet activation by potent agonists, also occurs when platelets adhere to biologically relevant matrix proteins, requires neither platelet aggregation nor the release of secondary agonists such as ADP and TxA, and can be initiated by at least some members of two additional classes of receptors.